• English
  • 简体中文
Login Register
Current Location: Home > Feedback Help Print

【结 构 式】

【分子编号】27554

【品名】1-[(3aR,8aS)-2,2-dimethyl-8,8a-dihydro-2H-indeno[1,2-d][1,3]oxazol-3(3aH)-yl]-1-propanone

【CA登记号】

【 分 子 式 】C15H19NO2

【 分 子 量 】245.3214

【元素组成】C 73.44% H 7.81% N 5.71% O 13.04%

与该中间体有关的原料药合成路线共 2 条

合成路线1

该中间体在本合成路线中的序号:(VII)

Preparation of the precursor alcohol (XI) is outlined in Scheme 1. Reduction of 2-bromo-5-methoxybenzoic acid (I) with borane-dimethylsulfide complex gave benzylic alcohol (II). After conversion of (II) to the corresponding mesylate, treatment with NaBr provided bromide (III). (1R,2S)-Aminoindanol (IV) was acylated with propionyl chloride to afford amide (V), which was converted to acetonide (VII) with 2-methoxypropene (VI) using pyridinium tosylate as the acid catalyst. Acetonide (VII) was then alkylated with bromide (III) in the presence of lithium hexamethyldisilazide at -35 C to give the chiral intermediate (VIII). Hydrolysis of acetonide at 10 C, followed by amide hydrolysis under reflux furnished a mixture of acid (IX) and methyl ester (X). This mixture was then reduced with LiAlH4 to provide the chiral alcohol (XI).

1 Frey, L.F.; Devine, P.N.; Tschaen, D.M.; Dolling, U.H.; Tillyer, R.D.; Kato, Y. (Banyu Pharmaceutical Co., Ltd.; Merck & Co., Inc.); Stereoselective deoxygenation reaction. EP 0923557; JP 1999514676; WO 9806700 .
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(I) 17819 2-bromo-5-methoxybenzoic acid 22921-68-2 C8H7BrO3 详情 详情
(II) 27551 (2-bromo-5-methoxyphenyl)methanol C8H9BrO2 详情 详情
(III) 27552 1-bromo-2-(bromomethyl)-4-methoxybenzene C8H8Br2O 详情 详情
(IV) 27559 (1R,2S)-1-amino-2,3-dihydro-1H-inden-2-ol C9H11NO 详情 详情
(V) 27553 N-[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]propanamide C12H15NO2 详情 详情
(VI) 17354 isopropenyl methyl ether; 2-methoxy-1-propene 116-11-0 C4H8O 详情 详情
(VII) 27554 1-[(3aR,8aS)-2,2-dimethyl-8,8a-dihydro-2H-indeno[1,2-d][1,3]oxazol-3(3aH)-yl]-1-propanone C15H19NO2 详情 详情
(VIII) 27555 (2S)-1-[(3aR,8aS)-2,2-dimethyl-8,8a-dihydro-2H-indeno[1,2-d][1,3]oxazol-3(3aH)-yl]-3-(2-bromo-5-methoxyphenyl)-2-methyl-1-propanone C23H26BrNO3 详情 详情
(IX) 27556 (2S)-3-(2-bromo-5-methoxyphenyl)-2-methylpropionic acid C11H13BrO3 详情 详情
(X) 27557 methyl (2S)-3-(2-bromo-5-methoxyphenyl)-2-methylpropanoate C12H15BrO3 详情 详情
(XI) 27558 (2S)-3-(2-bromo-5-methoxyphenyl)-2-methyl-1-propanol C11H15BrO2 详情 详情

合成路线2

该中间体在本合成路线中的序号:(X)

The intermediate 3-(2-bromo-5-methoxyphenyl)-2(S)-methyl-1-propanol tert-butyldimethylsilyl ether (XIV) has been obtained as follows: the reduction of 2-bromo-5-methoxybenzoic acid (VII) with NaBH4/BF3 gives the expected benzyl alcohol (VIII), which by treatment with SOCl2 is converted into the benzyl chloride (IX). The condensation of (IX) with the chiral auxiliary (X) by means of LIHMDS provides the 2(S)-methylpropionic acid derivative (XI). Elimination of the chiral auxiliary with sulfuric acid gives 3-(2-bromo-5-methoxyphenyl)-2(S)-methylpropionic acid (XII), which is reduced with NaBH4/BF3 to the corresponding alcohol (XIII). Finally, this compound is silylated to afford the intermediate (XIV) with TBDMS-Cl and imidazole.

1 Song, Z.J.; et al.; Practical asymetric synthesis of an endothelin receptor antagonist. J Org Chem 1999, 64, 26, 9658.
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(VII) 17819 2-bromo-5-methoxybenzoic acid 22921-68-2 C8H7BrO3 详情 详情
(VIII) 27551 (2-bromo-5-methoxyphenyl)methanol C8H9BrO2 详情 详情
(IX) 38553 1-bromo-2-(chloromethyl)-4-methoxybenzene; 4-bromo-3-(chloromethyl)phenyl methyl ether C8H8BrClO 详情 详情
(X) 27554 1-[(3aR,8aS)-2,2-dimethyl-8,8a-dihydro-2H-indeno[1,2-d][1,3]oxazol-3(3aH)-yl]-1-propanone C15H19NO2 详情 详情
(XI) 27555 (2S)-1-[(3aR,8aS)-2,2-dimethyl-8,8a-dihydro-2H-indeno[1,2-d][1,3]oxazol-3(3aH)-yl]-3-(2-bromo-5-methoxyphenyl)-2-methyl-1-propanone C23H26BrNO3 详情 详情
(XII) 27556 (2S)-3-(2-bromo-5-methoxyphenyl)-2-methylpropionic acid C11H13BrO3 详情 详情
(XIII) 27558 (2S)-3-(2-bromo-5-methoxyphenyl)-2-methyl-1-propanol C11H15BrO2 详情 详情
(XIV) 27567 4-bromo-3-((2S)-3-[[tert-butyl(dimethyl)silyl]oxy]-2-methylpropyl)phenyl methyl ether C17H29BrO2Si 详情 详情
Extended Information